Results 31 to 40 of about 131,065 (253)

Mortality in patients with successful initial response to highly active antiretroviral therapy is still higher than in non-HIV-infected individuals. [PDF]

, 2005
Mortality in HIV-infected patients has decreased dramatically since the introduction of highly active antiretroviral therapy (HAART). We analyzed progression to death in a population of 3678 antiretroviral treatment-naive patients from the ATHENA ...
Anderson, Roy M, ATHENA National Observational Cohort Study, Danner, Sven, de Wolf, Frank, Ghani, Azra C, Gras, Luuk, van Sighem, Ard   +6 more
core   +4 more sources

COVID-19 and chronological aging : senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? [PDF]

, 2020
COVID-19, also known as SARS-CoV-2, is a new emerging zoonotic corona virus of the SARS (Severe Acute Respiratory Syndrome) and the MERS (Middle East Respiratory Syndrome) family.
Auwerx, Blagosklonny, Blagosklonny, Blagosklonny, Colasurdo, Colson, Diaz-Quijano, Du, Erusalimsky, Gerontol, Gorospe, Hoffmann, Häkkinen, Jang, Li, Lisanti, Lisanti, Lu, Masternak, Munster, Musso, Nowakowski, Porter, Subbarao, Subbarao, Tanga, Tremblay, Wilce, Yaron, Yusof, Zhang   +30 more
core   +2 more sources

Binding of the SARS-CoV-2 spike protein to glycans [PDF]

Science Bulletin, 2020
AbstractThe pandemic of SARS-CoV-2 has caused a high number of deaths in the world. To combat it, it is necessary to develop a better understanding of how the virus infects host cells. Infection normally starts with the attachment of the virus to cell-surface glycans like heparan sulfate (HS) and sialic acid-containing oligosaccharides.
Hao, Wei, Ma, Bo, Li, Ziheng, Wang, Xiaoyu, Gao, Xiaopan, Li, Yaohao, Qin, Bo, Shang, Shiying, Cui, Sheng, Tan, Zhongping   +9 more
openaire   +2 more sources

SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies [PDF]

Infection, 2021
COVID-19 pandemic has emerged as a result of infection by the deadly pathogenic severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), causing enormous threats to humans. Coronaviruses are distinguished by a clove-like spike (S) protein, which plays a key role in viral pathogenesis, evolutions, and transmission.
Ahmed M. Almehdi, Ghalia Khoder, Aminah S. Alchakee, Azizeh T. Alsayyid, Nadin H. Sarg, Sameh S. M. Soliman   +5 more
openaire   +2 more sources

BSL2-compliant lethal mouse model of SARS-CoV-2 and variants of concern to evaluate therapeutics targeting the Spike protein

Frontiers in Immunology, 2022
Since first reported in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is rapidly acquiring mutations, particularly in the spike protein, that can modulate pathogenicity, transmission and antibody evasion leading to successive waves ...
Mohanraj Manangeeswaran, Derek D. C. Ireland, Seth G. Thacker, Ha-Na Lee, Logan Kelley-Baker, Aaron P. Lewkowicz, Paul W. Rothlauf, Paul W. Rothlauf, Marjorie Cornejo Pontelli, Louis-Marie Bloyet, Michael A. Eckhaus, Mirian I. Mendoza, Sean Whelan, Daniela Verthelyi   +13 more
doaj   +1 more source

Computational epitope map of SARS-CoV-2 spike protein

PLOS Computational Biology, 2021
The primary immunological target of COVID-19 vaccines is the SARS-CoV-2 spike (S) protein. S is exposed on the viral surface and mediates viral entry into the host cell. To identify possible antibody binding sites, we performed multi-microsecond molecular dynamics simulations of a 4.1 million atom system containing a patch of viral membrane with four ...
Sikora, Mateusz, von Bülow, Sören, Blanc, Florian E. C., Gecht, Michael, Covino, Roberto, Hummer, Gerhard   +5 more
openaire   +7 more sources

The SARS-CoV-2 spike protein: balancing stability and infectivity [PDF]

Cell Research, 2020
SARS-CoV-2 spike (S) glycoprotein is the key target of current vaccine development efforts to combat COVID-19; neutralizing antibodies bind S and interfere with S binding to its receptor, angiotensin-converting enzyme 2. Recent work reveals the molecular basis of increased infectivity of the globally prevailing D614G S mutation.
Berger, Imre, Schaffitzel, Christiane
openaire   +4 more sources

SARS-CoV-2 spike-protein targeted serology test results and their association with subsequent COVID-19-related outcomes

Frontiers in Public Health, 2023
ImportanceIn the absence of evidence of clinical utility, the United States' Centers for Disease Control and Prevention does not currently recommend the assessment of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike-protein antibody ...
Harvey W. Kaufman, Stanley Letovsky, William A. Meyer, Laura Gillim, Magdalene M. Assimon, Carly A. Kabelac, John W. Kroner, Shannon L. Reynolds, Marcia Eisenberg   +8 more
doaj   +1 more source

Protease inhibitors targeting coronavirus and filovirus entry. [PDF]

, 2015
In order to gain entry into cells, diverse viruses, including Ebola virus, SARS-coronavirus and the emerging MERS-coronavirus, depend on activation of their envelope glycoproteins by host cell proteases.
Agudelo, Juliet, Barnard, Dale, Carrion, Ricardo, Lu, Kai, McKerrow, James H, Nunneley, Jerritt W, Pöhlmann, Stefan, Renslo, Adam R, Simmons, Graham, Vedantham, Punitha, Zhou, Yanchen   +10 more
core   +1 more source

SARS-CoV-2 variants – Evolution, spike protein, and vaccines

Biomedical Journal, 2022
Despite the rising natural and vaccines mediated immunity, several countries have experienced a resurgence of the Coronavirus disease of 2019 (COVID-19) due to the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. From Alpha to Omicron, the variants of concern (VOC) have evolved several spike protein mutations that may
Kai-Wei K. Chen, Daniel Tsung-Ning Huang, Li-Min Huang   +2 more
openaire   +3 more sources